A phase 1, open label, single center, single dose, two-way crossover comparative bioavailability/bioequivalent study comparing Aspargo's Sildenafil Oral Spray, an oral liquid suspension formulation of sildenafil citrate, with VIAGRA® tablets in healthy male subjects.
Latest Information Update: 31 Jul 2024
Price :
$35 *
At a glance
- Drugs Sildenafil (Primary) ; Sildenafil
- Indications Erectile dysfunction
- Focus Pharmacokinetics
- Sponsors Aspargo Laboratories
- 30 Jul 2024 According to an Aspargo Laboratories media release, company seek to collaborate with the FDA to file an NDA for ASP-001 for the treatment of Erectile-dysfunction under the 505(b)2 regulatory pathway.
- 30 Jul 2024 According to an Aspargo Laboratories media release, the study results were published in the International Journal of Science and Research (IJSR).
- 30 Jul 2024 Results published in the Aspargo Laboratories media release.